SCHEMBL6465768

SCHEMBL6465768

CCN(CC)CCOc1ccc2nc(Nc3nc(OC(=O)C(F)(F)F)c4cccc(OC)c4n3)nc(C)c2c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 1/20 0.38
SRC P12931 2/20 0.37
YES1 P07947 1/20 0.37
MEN1 O00255 3/20 0.35
KMT2A Q03164 3/20 0.35
KDM4E B2RXH2 3/20 0.35
ALDH1A1 P00352 2/20 0.35
AGER Q15109 1/20 0.35
USP2 O75604 1/20 0.35
LMNA P02545 1/20 0.35
RAB9A P51151 1/20 0.35
GAA P10253 1/20 0.35
AVPR1B P47901 1/20 0.35
MAPT P10636 2/20 0.34
TDP1 Q9NUW8 2/20 0.34
PSMD14 O00487 1/20 0.34
APAF1 O14727 1/20 0.34
MITF O75030 1/20 0.34
HPGD P15428 1/20 0.34
HTT P42858 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6470898 0.90 MEN1 (0.36) MEN1KMT2AKDM4EALDH1A1USP2
SCHEMBL6470468 0.90 ADORA2A (0.39) AURKAMEN1KMT2AKDM4EALDH1A1
SCHEMBL6467974 0.89 KDR (0.38) AURKAMEN1KMT2AKDM4EALDH1A1
Trifluoroacetic Acid SCHEMBL6465761 0.88 AURKA (0.39) AURKASRCYES1MEN1KMT2A
SCHEMBL6467480 0.86 TLR7 (0.34) AURKAMEN1KMT2AKDM4EALDH1A1
SCHEMBL6467359 0.85 FGFR2 (0.37) AURKAMEN1KMT2AKDM4EALDH1A1
SCHEMBL6469291 0.85 MCHR1 (0.35) AURKAMEN1KMT2AKDM4EALDH1A1
SCHEMBL6466218 0.84 SRC (0.38) AURKASRCYES1MEN1KMT2A
SCHEMBL6467450 0.83 FGFR2 (0.40) AURKAMEN1KMT2AKDM4EALDH1A1
SCHEMBL6469716 0.82 ALDH1A1 (0.37) AURKAMEN1KMT2AKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050124562-A1 Bis-quinazoline compounds for the treatment of bacterial infections REPLIDYNE, INC. 2005-06-09 US claimed
WO-2005030131-A2 BIS-QUINAZOLINE COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS REPLIDYNE, INC (US) 2005-04-07 WO claimed
US-20050124562-A1 Bis-quinazoline compounds for the treatment of bacterial infections REPLIDYNE, INC. 2005-06-09 US disclosed
WO-2005030131-A2 BIS-QUINAZOLINE COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS REPLIDYNE, INC (US) 2005-04-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050124562-A1 Bis-quinazoline compounds for the treatment of bacterial infections POLI, POLK, POLB AURKA 1070/4885SRC 4282/4885YES1 3611/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.